Lack of Association between SLC30A8 Variants and Type 2 Diabetes in Mexican American Families

Table 1

Clinical characteristics of the SAFHS included in this study ().

Characteristic		Description
Age at enrolment (y)	1,383	39.17 (0.45)
Females	1,383	822 (59.43)
Waist (cm)	1,371	94.71 (0.47)
Central obesity (waist circumference ≥102 cm for males and ≥88 cm for females)	1,371	641 (46.75)
Body mass index (BMI, Kg/m^2)	1,372	29.24 (0.18)
Obesity (BMI ≥ 30 Kg/m^2)	1,372	531 (38.70)
Systolic blood pressure (SBP, mmHg)	1,372	120.38 (0.51)
Diastolic blood pressure (DBP, mmHg)	1,372	70.67 (0.28)
Hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg)	1,372	247 (18.00)
Type 2 diabetes		169 (20.58)
Prevalent T2D at baseline visit	1,383	208 (15.04)
Incident T2D detected during follow-up^†	913	149 (16.32)
Ever T2D	1,383	357 (25.81)
Fasting glucose (mmol/L)^†	1,171	4.82 (0.02)
2-hour postchallenge glucose (mmol/L)^†	1,143	5.61 (0.05)
Fasting insulin^†	1,153	14.11 (0.46)
2-hour postchallenge insulin^†	1,115	76.86 (2.19)
HOMA-IR^†	1,153	3.16 (0.13)
HOMA-β^†	1,153	19.38 (1.67)
Total serum cholesterol (mg/dL)	1,379	189.27 (1.06)
Serum triglycerides (mg/dL)	1,379	150.10 (3.48)
HDL cholesterol (mg/dL)	1,378	50.14 (0.35)
Medication use at baseline
Antihypertensive medications	1,376	132 (9.59)
Lipid lowering medications	1,376	25 (1.82)

Number of individuals for whom data was available.
Numbers indicate mean (SE) for continuous variables and (%) for categorical variables.
^†These variables are reported only for individuals who did not have T2D at baseline.